NTLA - Intellia Therapeutics, Inc.
13.45 0.00 (0.00%)
After hours: 4:15PM EST
| Previous Close | 13.86 |
| Open | 14.10 |
| Bid | 13.42 x 900 |
| Ask | 13.43 x 4000 |
| Day's Range | 13.17 - 14.08 |
| 52 Week Range | 10.26 - 19.00 |
| Volume | 774,833 |
| Avg. Volume | 663,129 |
| Market Cap | 657.467M |
| Beta (5Y Monthly) | 2.80 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.97 |
| Earnings Date | Jan 08, 2020 - Jan 09, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 27.59 |
- Simply Wall St.
Here's Why We're Not Too Worried About Intellia Therapeutics's (NASDAQ:NTLA) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
- GlobeNewswire
Intellia Therapeutics Presents New Data From Its Engineered Cell Therapy and In Vivo Programs at Keystone Symposia’s Engineering the Genome Conference
Intellia Therapeutics, Inc. (NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, is presenting new data from two of its development programs at Keystone Symposia’s Engineering the Genome Conference, a joint meeting with the Emerging Cellular Therapies: Cancer and Beyond Conference, taking place Feb. 8-12, 2020, in Banff, Canada. Intellia researchers are presenting data in support of the company’s lead engineered cell therapy development candidate, NTLA-5001 for the treatment of the hematological cancer, acute myeloid leukemia (AML).
- Zacks
Implied Volatility Surging for Intellia (NTLA) Stock Options
Investors need to pay close attention to Intellia (NTLA) stock based on the movements in the options market lately.
- American City Business Journals
European ruling threatens Broad's CRISPR gene-editing patents
The saga over who owns the valuable patents that cover CRISPR/Cas9 gene editing took a new turn this week with a court decision that goes against the Broad Institute of Harvard and MIT and two local startups.
- GlobeNewswire
Intellia Therapeutics Highlights Recent Progress and Anticipated 2020 Milestones
Intellia Therapeutics, Inc. (NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today provided an update on recent progress and the Company’s 2020 priorities and expected milestones. With milestones anticipated across our pipeline, we are making important progress towards the development of curative treatments for severe diseases.
- Investor's Business Daily
Gene-Editing Stocks Dive As Creator Of CRISPR Babies Sent To Prison
Shares of CRISPR gene-editing companies tumbled Monday after the Chinese scientist who created the world's first genetically edited babies was sentenced to three years behind bars.
- Zacks
Has Intellia Therapeutics (NTLA) Outpaced Other Medical Stocks This Year?
Is (NTLA) Outperforming Other Medical Stocks This Year?
- American City Business Journals
Atlas, MPM, Partners funnel $49M into a new gene-silencing startup
Two of the industry’s leading gene-editing experts have unveiled their next venture: a gene-silencing startup called Triplet Therapeutics.
- Insider Monkey
Did Hedge Funds Drop The Ball On Intellia Therapeutics, Inc. (NTLA) ?
Like everyone else, elite investors make mistakes. Some of their top consensus picks, such as Amazon, Facebook and Alibaba, have not done well in Q4 of 2018 due to various reasons. Nevertheless, the data show elite investors' consensus picks have done well on average over the long-term. The top 20 stocks among hedge funds beat […]
- Simply Wall St.
Did Intellia Therapeutics, Inc. (NASDAQ:NTLA) Insiders Buy Up More Shares?
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...
- Zacks
Gene Therapy the Next Best Thing: Here's Why (Revised)
Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.
- American City Business Journals
Novartis-linked biotech firm raises $56M for new spinouts
After signing two back-to-back deals with Novartis this year, small Boston-based startup IFM Therapeutics is ramping up its business development with a new incubator.
- GlobeNewswire
Intellia Therapeutics to Present at Evercore ISI 2nd Annual HealthCONx Conference
CAMBRIDGE, Mass., Nov. 26, 2019 -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9.
- Thomson Reuters StreetEvents
Edited Transcript of NTLA earnings conference call or presentation 31-Oct-19 12:00pm GMT
Q3 2019 Intellia Therapeutics Inc Earnings Call
- Zacks
Vertex, CRISPR's Gene Editing Drug Shows Positive Early Data
Vertex (VRTX) and partner CRISPR Therapeutics announce positive early data from two studies on gene-editing drug CTX001 for the treatment of beta-thalassemia and sickle cell disease.
- American City Business Journals
CRISPR Therapeutics stock jumps on early gene editing data
CRISPR Therapeutics and Vertex Pharmaceuticals released the first data from their early-stage trial testing the safety and effectiveness of a potential cure for the genetic blood disorders sickle cell disease and beta thalassemia.
- Zacks
Axovant's GM1 Gangliosidosis Candidate Gets Orphan Drug Tag
The FDA grants Orphan Drug status to Axovant's (AXGT) gene therapy candidate, AXO-AAV-GM1, being developed for the treatment of GM1 gangliosidosis. Shares decline despite the positive news.
- Zacks
Intellia Therapeutics, Inc. (NTLA) Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor in Intellia Therapeutics, Inc. (NTLA).
- American City Business Journals
These 36 Mass. firms made Deloitte's Technology Fast 500
Massachusetts is home to 36 of the 500 companies making this year’s ranking, with three local firms making the top 100 — including the No. 2 spot.
- Zacks
Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Tops Revenue Estimates
Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of 19.67% and 16.15%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- Yahoo Finance Video
Axsome Therapeutics jumps as migraine drug hits goals in late-stage trial
Axsome Therapeutics is on a tear this year - with shares skyrocketing over 3,000%. This comes as the biotech company's migraine drug posted successful results in a late-stage study. Yahoo Finance's Anjalee Khemlani joins Seana Smith on The Ticker to discuss.
